| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Retrospective Study |
| Article Title |
Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Deng-Feng Ren, Fang-Chao Zheng, Jun-Hui Zhao, Guo-Shuang Shen, Raees Ahmad, Shui-Sheng Zhang, Yu Zhang, Jie Kan, Li Dong, Zi-Yi Wang, Fu-Xing Zhao and Jiu-Da Zhao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Thousand Talents of Program of High-end Innovation of Qinghai Province in China |
|
| the Clinical Oncology Medical Center of Qinghai Province in China |
2018-SF-113 |
|
| Corresponding Author |
Jiu-Da Zhao, MD, Professor, Department of Medical Oncology, Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, No. 29, Tongren Road, Xining 810000, Qinghai Province, China. jiudazhao@126.com |
| Key Words |
Gastric cancer; D2 gastrectomy; Adjuvant chemotherapy; S-1; Oxaliplatin; Capecitabine |
| Core Tip |
Based on the therapeutic efficacy of both S-1 mono-therapy and oxaliplatin plus capecitabine regimen in ACTS-gastric cancer (GC) and CLASSIC study, we conducted the multi-institutional research using propensity score-matched analysis to evaluate whether patients after D2 resection benefit from adjuvant chemotherapy with S-1 plus oxaliplatin (SOX). Here, we firstly report that SOX adjuvant chemotherapy, compared with surgery alone, significantly improves disease-free survival and overall survival in stage ⅠB-ⅢC GC patients undergoing D2 resection with accepted side effects. |
| Publish Date |
2018-09-26 09:00 |
| Citation |
Ren DF, Zheng FC, Zhao JH, Shen GS, Ahmad R, Zhang SS, Zhang Y, Kan J, Dong L, Wang ZY, Zhao FX, Zhao JD. Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study. World J Clin Cases 2018; 6(10): 373-383 |
| URL |
http://www.wjgnet.com/2307-8960/full/v6/i10/373.htm |
| DOI |
http://dx.doi.org/10.12998/wjcc.v6.i10.373 |
